Talk Bio

Senior source denies any merger discussions between AstraZeneca and Bristol Myers Squibb, stating there is no deal and never was a deal to be done. Reports indicate that preliminary talks were held but have since ended or never progressed. Both companies have declined to comment on the status of the talks. Initial speculation about a $400 billion merger led to significant stock movements but subsequent reports have cooled the merger buzz. Sources: AstraZeneca stock falls as investors balk at reported Bristol Myers tie-up AstraZeneca and Bristol Myers Squibb merger talks denied - Quartz Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal ... AstraZeneca investors balk at prospect of $400 billion Bristol Myers ... AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed' FTSE 100 dips as AstraZeneca slides on Bristol Myers tie- ... AstraZeneca falls to third-largest UK company amid US merger talks AstraZen...